IDEXX Laboratories, Inc. IDXX
NASDAQ · Healthcare · Medical - Diagnostics & Research
$676.21
Close on Fri, 20 Nov 2026 · market value $53.3B
What the price is betting on
Priced for a lot to go rightAt $676, the price assumes revenue grows about 25% a year for five years, from $4.7B to about $12B by FY2030. That is about three times what analysts expect for the next two years and about three times the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 11% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than IDXX? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$245
Base
$297
Bull
$359
Today $676
- Bear $245. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $297. Cash flow grows 9% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $359. Cash flow grows 13% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$4.9B$4.7B, below the path
- FY2027$6.2B$5.2B, below the path
- FY2028$7.7B$5.7B, below the path
- FY2029$9.6B$6.2B, below the path
- FY2030$12B$6.8B, below the path
Each year's revenue at 25% growth from $4.7B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Diagnostics & Research · listed on NASDAQ
- Revenue, FY2025
- $4.3B
- Growth, 3 years a year
- 9.2%
- Cash margin
- 25%
- Net debt
- $897M
- Shares, 3-year change
- −4.6%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.